tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatitis, Seborrheic D012628 10 associated lipids
Vision Disorders D014786 10 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Long QT Syndrome D008133 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dyspnea D004417 10 associated lipids
Hemophilia A D006467 10 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Glycosuria D006029 10 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Thinness D013851 11 associated lipids
Shock, Septic D012772 11 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Dehydration D003681 11 associated lipids
Exanthema D005076 11 associated lipids
Hyperpigmentation D017495 11 associated lipids
Influenza, Human D007251 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock D012769 11 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Eye Diseases D005128 12 associated lipids
Crohn Disease D003424 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Keloid D007627 12 associated lipids
Hypertension, Portal D006975 12 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Retinoblastoma D012175 12 associated lipids
Osteoporosis D010024 12 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Listeriosis D008088 12 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Critical Illness D016638 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Urticaria D014581 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Biliary Fistula D001658 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Corneal Diseases D003316 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Alopecia D000505 14 associated lipids
Stomatitis D013280 14 associated lipids
Vasculitis D014657 14 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Neutropenia D009503 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Down Syndrome D004314 18 associated lipids
Albuminuria D000419 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Ischemia D007511 18 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Translocation, Genetic D014178 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. 2003 Am. J. Transplant. pmid:12752315
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kim EJ et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 2014 Am. J. Transplant. pmid:24354871
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Frassetto LA et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. 2007 Am. J. Transplant. pmid:17949460
Cosio FG and Larson TS Cardiovascular disease after transplantation: do we know all of the variables? 2003 Am. J. Transplant. pmid:12859523
Levitsky J and Feng S Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. 2014 Am. J. Transplant. pmid:24620373
Krämer BK et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. 2003 Am. J. Transplant. pmid:12859533
Ciancio G et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. 2003 Am. J. Transplant. pmid:12859538
Cavadas PC et al. Bilateral trans-humeral arm transplantation: result at 2 years. 2011 Am. J. Transplant. pmid:21521475
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Qazi Y et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. 2017 Am. J. Transplant. pmid:27775865
Coghill AE et al. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. 2016 Am. J. Transplant. pmid:26824445
Asrani SK et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. 2014 Am. J. Transplant. pmid:24456026
Song L et al. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. 2017 Am. J. Transplant. pmid:27598231
Kurtz J et al. Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. 2003 Am. J. Transplant. pmid:12814472
Egli A et al. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. 2010 Am. J. Transplant. pmid:20840474
Zafrani L et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. 2009 Am. J. Transplant. pmid:19538494
Touzot M et al. Renal transplantation in HIV-infected patients: the Paris experience. 2010 Am. J. Transplant. pmid:20840478
Krämer BK et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. 2010 Am. J. Transplant. pmid:20840480
Trunečka P et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 2010 Am. J. Transplant. pmid:20840481
Ekberg H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. 2009 Am. J. Transplant. pmid:19563339
Mehra MR et al. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. 2006 Am. J. Transplant. pmid:16686745
Grimm M et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. 2006 Am. J. Transplant. pmid:16686762
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Sis B et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. 2006 Am. J. Transplant. pmid:16686769
Duncan FJ et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. 2007 Am. J. Transplant. pmid:17941958
Hu X et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. 2016 Am. J. Transplant. pmid:26749344
Cameron AM et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. 2016 Am. J. Transplant. pmid:26748958
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Budde K et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. 2010 Am. J. Transplant. pmid:20121745
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Al-Massarani G et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. 2008 Am. J. Transplant. pmid:18925903
Bouamar R et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). 2013 Am. J. Transplant. pmid:23480233
Busque S et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. 2011 Am. J. Transplant. pmid:21943027
Hamdy AF et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. 2005 Am. J. Transplant. pmid:16162204
Kaufman DB et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. 2005 Am. J. Transplant. pmid:16162205
Naesens M et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. 2007 Am. J. Transplant. pmid:17608835
Schwarz A et al. Polyoma virus nephropathy in native kidneys after lung transplantation. 2005 Am. J. Transplant. pmid:16162212
Flechner SM et al. Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. 2010 Am. J. Transplant. pmid:20883540
Benítez CE et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. 2010 Am. J. Transplant. pmid:20883560
Shemesh E et al. The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. 2017 Am. J. Transplant. pmid:28321975
Chisholm-Burns MA et al. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23819827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Muthusamy AS et al. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. 2008 Am. J. Transplant. pmid:18828772
Van Laecke S et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 2009 Am. J. Transplant. pmid:19624560
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Srinivas TR et al. The noninferiority trial: don't don't do it. 2010 Am. J. Transplant. pmid:21087412
Pescovitz MD et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 Am. J. Transplant. pmid:19663892
Bryan CF et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. 2007 Am. J. Transplant. pmid:17359511
Vincenti F et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. 2007 Am. J. Transplant. pmid:17359512
Diaz-Siso JR et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. 2015 Am. J. Transplant. pmid:25777324
Cendales L et al. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 2015 Am. J. Transplant. pmid:25773260
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Rodriguez-Rodriguez AE et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. 2013 Am. J. Transplant. pmid:23651473
Klintmalm GB et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. 2014 Am. J. Transplant. pmid:25041339
Jaksch P et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. 2014 Am. J. Transplant. pmid:25039364
Neuberger JM et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. 2009 Am. J. Transplant. pmid:19120077
Momper JD et al. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. 2011 Am. J. Transplant. pmid:21714845
Tan HP et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. 2009 Am. J. Transplant. pmid:19120078
TruneÄŒka P et al. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. 2015 Am. J. Transplant. pmid:25707487
Ashman N et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. 2009 Am. J. Transplant. pmid:19120084
Adam R et al. Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. 2015 Am. J. Transplant. pmid:25703527
Asrani SK and O'Leary JG Can one pill a day keep rejection away? 2015 Am. J. Transplant. pmid:25703394
Oetting WS et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. 2016 Am. J. Transplant. pmid:26485092
Badri P et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. 2015 Am. J. Transplant. pmid:25708713
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Luan FL et al. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. 2008 Am. J. Transplant. pmid:18786231
Woywodt A et al. Different preparations of tacrolimus and medication errors. 2008 Am. J. Transplant. pmid:18786238
Servais A et al. Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. 2011 Am. J. Transplant. pmid:21672152
Carenco C et al. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. 2015 Am. J. Transplant. pmid:25648361
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Mulay AV et al. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. 2009 Am. J. Transplant. pmid:19353768
Ogawa T et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. 2007 Am. J. Transplant. pmid:17229077
Miriuka SG et al. mTOR inhibition induces endothelial progenitor cell death. 2006 Am. J. Transplant. pmid:16796720
Bourdeaux C et al. Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. 2007 Am. J. Transplant. pmid:17173657
Heller T et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. 2007 Am. J. Transplant. pmid:17532750
Schrepfer S et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. 2007 Am. J. Transplant. pmid:17532751
Ryan CM and Swanson DP clinical research, innovative practice and IRB review: identifying and respecting boundaries. 2007 Am. J. Transplant. pmid:17331113
Rostaing L et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. 2013 Am. J. Transplant. pmid:23730730
Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. 2004 Am. J. Transplant. pmid:15268733
Schussler T et al. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 Am. J. Transplant. pmid:15268744
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Posselt AM et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. 2010 Am. J. Transplant. pmid:20659093
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Ciancio G et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. 2012 Am. J. Transplant. pmid:22946986
Jacobson PA et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. 2012 Am. J. Transplant. pmid:22947444
De Simone P et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 2012 Am. J. Transplant. pmid:22882750
Echeverri GJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. 2009 Am. J. Transplant. pmid:19775318
Gaston RS et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. 2009 Am. J. Transplant. pmid:19459794
Lake JR et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. 2005 Am. J. Transplant. pmid:16303011
Mandelbrot DA et al. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. 2015 Am. J. Transplant. pmid:26176342